| |
KOMISJA NADZORU FINANSOWEGO |
|
| |
|
|
Raport bieżący nr |
21 |
/ |
2020 |
|
|
|
| |
Data sporządzenia: |
2020-09-09 |
|
|
|
|
|
|
|
|
|
| |
Skrócona nazwa emitenta |
|
|
|
|
|
|
|
|
|
| |
MILESTONE MEDICAL |
|
| |
Temat |
|
|
|
|
|
|
|
|
|
|
| |
The update on commercial roll-out and active trials of CompuFlo® Epidural System at
premier hospitals
|
|
| |
Podstawa prawna |
|
|
|
|
|
|
|
|
| |
Art. 17 ust. 1 MAR - informacje poufne.
|
|
| |
Treść raportu: |
|
|
|
|
|
|
|
|
|
| |
The Board of Directors of Milestone Medical Inc. _WAR: MMD, “the Company", “the Issuer"_
today provided a business update regarding the commercial roll-out of its CompuFlo®
Epidural System and CathCheck™ technology.
With COVID-19 infections declining in certain regions, and a number of hospitals re-opening
to outside vendors, the Board of Directors of the Company is advancing sales efforts
around the CompuFlo® Epidural System and CathCheck™ technology. To support the hospitals
in performing procedures during the pandemic, the Board of Directors of the Issuer
decided to make the CompuFlo instrument more readily available to hospitals by lending
the instrument to the hospital, in exchange for a commitment to purchase a minimum
number of disposables. This offering is limited to the first hospitals that sign up
for this program. At the same time, the Company is partnering with anesthesiologists,
in order to approach the purchasing departments of the hospitals together. The
Board of Directors of the Company believes that the current strategy allows the Issuer
to streamline the Value Analysis Team _VAT_ approval process, and thereby shorten
the sales cycle. The response thus far has been encouraging, and the Company is increasing
new trials in major hospitals over the coming weeks. The Board of Directors of the
Company looks forward to finalizing agreements with several premier hospitals in the
near future as the sales pipeline is more robust than ever.
|
|
|